april 3, 2020
Gained Rights to Product Candidate, CZN001 (renamed HZN-825), a Potential Treatment for Diffuse Cutaneous Systemic Sclerosis; a Rare Rheumatic Disease with No FDA-Approved Treatment Compelling Fit with Horizon’s Strategy to Acquire and Develop Medicines Targeting Diseases with High Unmet Need with Focus on Its Core Therapeutic Areas DUBLIN, (BUSINESS WIRE), Apr. 2, 2020 – Horizon...


Danmark får sin første kandidatuddannelse i neurovidenskab
4. juni 2020
Nye alkohol-gener vælter frem
2. juni 2020
Video: Mød fem professorer, der har viet deres hjerne til andres
14. maj 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge